RepliCel Life Sciences Inc.
RP
Rangering i aksjer
#38675
Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a... Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a regenerative medicine company dedicated to developing innovative autologous cell therapies. These treatments are designed to correct functional cellular deficiencies by harnessing a patient's own cells. The process involves isolating cells from harvested tissues, significantly expanding them in a controlled laboratory environment, and subsequently applying them therapeutically. The company's developmental portfolio includes several key product candidates: RCT-01 targets chronic tendinosis, RCS-01 addresses aging and sun-damaged skin, and RCH-01 is aimed at treating hair loss. Additionally, RepliCel is advancing RCI-02, a specialized dermal injection device. RepliCel has established significant strategic alliances. It holds a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. to establish a clinical research program and facilitate the commercialization of RCS-01 and RCT-01. A similar collaboration exists with Shiseido Company, Limited, focusing on the clinical research program for RCH-01. Furthermore, the company is engaged in a research project agreement with the University of British Columbia, contributing to the creation of a comprehensive hair follicle cell data map.
Aksjekurs
$0.01100905
Sist synkronisert: 2025-02-28
Markedsverdi
$810.02K
Endring (1 dag)
58.98%
Endring (1 år)
10,909.05%
Land
CA
Handel RepliCel Life Sciences Inc. (RP)
Kategori
Healthcare
P/B-forhold for RepliCel Life Sciences Inc. (RP)
P/B-forhold per 2026 TTM: 0
Ifølge RepliCel Life Sciences Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for RepliCel Life Sciences Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | - |
NL
|
